COL6A3 and obesity due to melanocortin 4 receptor deficiency: Given our finding that reducing levels of COL6A3 and its cleaved product endotrophin can reduce the risk of CAD without apparent adverse health outcomes, directly targeting endotrophin could be an attractive therapeutic approach that may be particularly effective in individuals with obesity.